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Abstract: The emergence of Candida auris is considered as one of the most serious problems associated
with nosocomial transmission and with infection control practices in hospital environment. This
multidrug resistant species is rapidly spreading worldwide, with several described outbreaks. Until
now, this species has been isolated from different hospital surfaces, where it can survive for long
periods. There are multiple unanswered questions regarding C. auris, such as prevalence in population,
environmental contamination, effectiveness of infection prevention and control, and impact on patient
mortality. In order to understand how it spreads and discover possible reservoirs, it is essential
to know the ecology, natural environment, and distribution of this species. It is also important to
explore possible reasons to this recent emergence, namely the environmental presence of azoles or
the possible effect of climate change on this sudden emergence. This review aims to discuss some of
the most challenging issues that we need to have in mind in the management of C. auris and to raise
the awareness to its presence in specific indoor environments as hospital settings.
Keywords: Candida auris; hospital infection; environmental contamination; horizontal transmission;
azole resistance
1. Introduction
Infections caused by yeasts belonging to Candida genus are classified as candidiasis (includes
candidemia). From 150 Candida species described, some are a part of our normal microbiota and
only 10% are known to be responsible for infections in humans, being C. albicans, the most frequent
etiological agent [1].
Several Candida species are known to be pathogenic in healthy individuals, affecting skin and
mucous membranes. However, over the last two decades, invasive candidiasis is emerging in critically
ill patients, due to several factors such as aging populations with many comorbidities, extended
stays in hospital wards, diabetes, use of invasive devices, broad-spectrum antibiotics, extensive
surgeries, stem cell transplantation, and immunosuppression (AIDS, and immunosuppressive and
immunomodulatory therapy) [2].
Candida infections are ranked as the most common of nosocomial infections caused by fungi,
emerging as a serious public health problem worldwide [3].
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Invasive candidiasis may be caused by more than 150 Candida species [3]. C. albicans is the most
frequent species causing invasive candidiasis in human patients, however, in the last decade, a wide
range of non-albicans species have progressively been rising as emergent human pathogens, mainly
C. glabrata, C. parapsilosis, and C. tropicalis and Pichia kudriavzevii (former C. krusei) [2,3]. One of the
main reasons for this rising is the introduction of fluconazole prophylaxis/therapy, which led to the
positive selection of azole-less susceptible/resistant species [4].
C. auris was first described in 2009, after being isolated from the external ear canal of an inpatient
in a Japanese hospital [5]. Since then, reports of C. auris infections, including fungemia, wound
infections and otitis, have been most commonly identified [6]. Until now, this species has been
associated with hospital environment, being found in several different hospital surfaces, where it
can survive for long periods. This multidrug resistant species is rapidly spreading worldwide, with
several described outbreaks. One of those was found to be linked to reusable axillary temperature
probes [7]. Commercially available biochemical-based tests, used in laboratories to identify fungi,
cannot differentiate C. auris from some other yeasts species, if there was no update of the associated
database [8]. Hence, C. auris is considered as one of the most serious emerging pathogen, with severe
public health implications. This review aims to discuss some of the most challenging issues that should
be the focus in the management of C. auris.
2. What Is Already Known About This Topic?
2.1. Which Specific Conditions Can Explain the Recent Increase of Candida Infections and the Recent
Emergence of C. auris?
In recent years, C. auris has emerged simultaneously in different countries as a new species able to
colonize and infect patients, causing death in a high proportion of these last ones.
Until 2009, only four isolates were retrospectively identified as C. auris. Three of these isolates
were initially identified as C. haemulonii and one was not identified to species level [9,10].
In fact, with the purpose to investigate whether C. auris had emerged in recent times or if it had
been misidentified in the past, an extensive investigation was conducted within the pool of uncommon
Candida spp. included in the SENTRY global fungal collection (15,271 isolates of Candida spp. collected
during 2004–2015 from Asia, Europe, Latin America, and North America) [11]. This study identified a
single C. auris isolate from Pakistan dating back to 2008, which had not been previously recognized.
In 2011, the first three cases of bloodstream fungemia caused by C. auris were reported, highlighting
antifungal resistance and the ability to cause invasive infections and from those, one was obtained
from a microbiological sample collected in 1996 as invasive fungal infection isolate [6]. There are no
other unidentified C. auris strains prior to 1996 [9].
The US Centers for Disease Control and Prevention (CDC) reviews of other large-scale isolate
collections also confirmed the finding that C. auris, as well as C. haemulonii, were relatively rare before
2009. These findings suggest that C. auris emerged as a cause of human infections primarily in the last
decade [10].
This global emergence has been attributed to the near-simultaneous appearance in five
geographically restricted clades, with clonal transmission identified both within and across health care
facilities, but the reasons for this simultaneous emergence are not known [10,12,13].
The widespread use of antifungal drugs has been suggested as a contributory cause in the
emergence of C. auris [14]. One other hypothesis is the rising ambient temperatures (caused by human
activities) that might have selected thermotolerant yeasts in wetlands; and that C. auris might have
spread through different ecosystems and hosts, such as avian birds. The tolerance to high salinity
levels and ability to grow at 42 ◦C are points that strengthen this latter hypothesis [15–17].
Increasing number of travels to foreigner countries and exposure to healthcare in countries with
extensive C. auris transmission as well as higher flow of migrants are factors that can contribute to the
quick dissemination of this species. Further, a higher frequency higher frequency of C. auris was found
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in public hospitals in comparison to the private ones, which may be connected to overcrowding and
compromised infection control measures [14].
Increasing rates of antifungal usage at a global level are also pointed out as other potential reason.
Initial epidemiologic characterization of C. auris cases found that many patients with C. auris infection
had been receiving antifungal drugs at the time C. auris was isolated, suggesting that drug pressure
could have resulted in emergence of this resistant organism, at least within healthcare settings [10].
Multidrug-resistant C. auris may also find a reservoir in facilities such as skilled nursing units for
ventilated patients and long-term acute care hospitals. Hospitals are discharging high-acuity patients
to these other facilities, which do not have a comparable level of infection prevention education and
staffing, with possible easier transmission to other patients.
The main reasons for the high impact of this Candida species are:
(a) Most C. auris isolates are resistant to fluconazole. However, and contrarily to other fluconazole
resistant Candida species, in C. auris resistance to other antifungal agents has also been reported, and
some isolates are described as multiresistant, since they are resistant to the three classes of antifungal
agents available (azoles, polyenes and echinocandins). Also, C. auris has higher potential to disseminate
than other Candida species.
(b) C. auris appears to survive on surfaces for long periods of time and to have high ability
for transmission among patients in a hospital environment, possibly associated with environmental
contamination or transitory colonization of medical personnel, visitors or medical devices [18].
(c) It is a species of difficult identification since it can be confused with other Candida species.
Their correct identification is made through biochemical or mass spectrometry methods, whose devices
already have their databases updated, that is, they already contain this species’ profile. Confirmation
of species identification should be done by sequencing specific DNA regions or specific PCR.
2.2. Which Is the Global Burden of These Fungal Infections?
There are no worldwide estimates of the number of C. auris infection/colonization cases. It is now
reported in more than 35 countries, in all continents except Antarctica (Figure 1) [19]. C. auris has
rapidly emerged as a major cause of candidemia worldwide, surpassing the number of cases caused
by C. glabrata, C. tropicalis, and Pichia kudriavzevii in South Africa [20]. Reports of the first cases of
infections/colonizations in different countries have been widely described [21–34]. In some of these
countries, extensive transmission of C. auris has been documented in more than one hospital [35].
In the United States, C. auris was made nationally notifiable in 2018. Until March 2019,
613 confirmed cases and 1123 colonized patients have been reported in eight states [19]. The majority
of the reported infections involved critically ill patients [14].
In Europe, from 2013 to 2017, a total of 620 C. auris cases were reported from six countries to
European Centre for Disease Prevention and Control (ECDC). This number arose during an online
survey that included reports from 29 of 30 EU/EEA countries. Cases were reported from Spain (n = 388),
United Kingdom (n = 221), Germany (n = 7), France (n = 2), Belgium (n = 1) and Norway (n = 1).
Regarding the other countries, nor colonisation or invasive infection had been detected (in 15 countries)
and in seven other countries no information were made available at the national level by the National
Focal Points [36].
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Figure 1. Global epidemiology of Candida auris for November 2019 (image adapted from CDC [19]).
Single cases were reported from Austria, Belgium, Chile, Italy, Greece, Egypt, Iran, Norway, Switzerland,
Taiwan and United Arab Emirates. Multiple cases and extensive hospital transmission were reported
from Australia, Bangladesh, Canada, China, Colombia, France, Germany, India, Israel, Japan, Kenya,
Kuwait, Malaysia, Paskistan, Netherlands, Oman, Panama, Russia, Saudi Arabia, Singapore, South
Africa, South Korea, Spain, UK, USA and Venezuela [20–35].
2.3. Why Is C. auris Is Reported as Rapidly Spreading Worldwide as an Agent of
Hospital-Associated Outbreaks?
According to recent studies, the worldwide C. auris population consists of distinct clades
that harbour nearly identical strains within each clade (East Asia, South Asia, Africa, and South
America) [11,13]. Recently, an isolate from Iran was found to be genetically distinct from the four
existing clades, having a difference of >200,000 single-nucleotide polymorphisms compared with the
other four clades and may constitute the fifth clade [13]. The reasons for the simultaneous emergence
of this species in different geographic areas are not known. Hypotheses have included possible animal
reservoirs, as well as environmental changes that may have led to this situation [10].
Whole genome sequencing (WGS) was used to show that C. auris isolates from four Indian
hospitals were highly related and their findings were suggestive of clonal transmission [37]. Similar
results were reported for Pakistan, South Africa, Venezuela, and Colombia, where C auris isolates
within each country were highly related. However, large genetic differences were observed between
isolates in different global regions, indicating that C. auris has substantial phylogeographical structure.
Whole-genome sequencing identified a difference of 40,000–140,000 single nucle ti e polymorphisms
(SNPs) between C. auris isolates from the different regions (East Asia, South Asia, Africa, and South
America) [11]. The cases detected in the USA did not represe t a new clade, but they were genetically
linked to the previously defined geographical clades, which suggested several introductions of C. auris
into the US health-care system in different instances [38]. The same was observed in a E ropean hospital
using amplified fragment length polymorphism (AFLP) to analyse C. auris isolates from an outbreak in
a cardi -thoracic center located in the United Kingdom with other isolates from ther countries in order
to identify a eographic origin of the ongoing o tbreak [39]. AFLP analysis suggested that the Lo on
is lates formed a distinct cluster compared to other global isolates but WGS a alysis showed placed
the United Kingdom outbrea in the India/Pakistan clade, demonstrating an Asian origin. When all
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isolates from the outbreak were compared, there was a weak support for the monophyletic status of
isolates within the hospital, suggesting that multiple introductions of C. auris occurred as well [40].
C. auris genome is also very different from other Candida species, which may explain its
unique features in regards dissemination pattern, susceptibility, virulence attributes, among others.
A phylogenetic analysis integrating the genomes of C. auris, C. haemulonii, C. duobushaemulonii, and
C. pseudohaemulonii with other Candida species was performed. Comparing the genomes of these four
emerging species to those of other Candida species, genes linked to drug resistance and virulence
were identified, including expanded families of transporters and lipases, as well as mutations and
copy number variants in ERG11 [41]. Gene expression analysis identified transporters and metabolic
regulators specific to C. auris and those conserved with related species.
2.4. C. auris Has Been Identified as Agent of Hospital-Associated Infections. Are There Community Acquired
C. auris Infections?
A report of screening on admission to the hospital (potentially reflecting burden of C. auris in
the community) in the United Kingdom found that just one in over 2200 of admitted patients were
positive for C. auris. However, this screening was performed in a low prevalence country, and data
about the patient’s prior healthcare exposures was not available, limiting interpretation about whether
C. auris colonization was acquired in the community or in the healthcare setting [39]. A smaller
admission screening program at a trauma intensive care unit in India, a country with more documented
transmission, did not find any patients with C. auris colonization at admission [42]. In the United
States, nearly all patients have had recent healthcare exposure [10].
C. auris invasive infection and colonization have been identified almost exclusively in patients
in high-dependency areas with the highest degree of medical intervention. Although transmission
of C. auris in healthcare settings has been well documented, less is known about transmission in the
community [10]. The possibility of this yeast also spreading into the community, farms and general
environment should not be lost sight of [43]. An animal or environmental reservoir for C. auris has not
yet been identified. Only a small proportion of cases being community-acquired is evocative of the
high frequency and predilection for nosocomial transmission [44]. This suggests that a community
reservoir may be unlikely; transmission to contacts in the healthcare settings is a significant risk that
may depend on colonization density [44]. The role of health care workers in spreading C. auris is
still unknown. However, during investigation of the outbreak in the United Kingdom, C. auris was
isolated from the nares of a nurse who was providing care for a patient who was heavily colonized [39].
Moreover, an outbreak investigation in Colombia isolated C. auris from the hands of two health care
workers and the groin of one out of six health care workers. Whole-genome sequencing established
that these were genetically identical to strains isolated from a patient and surround environment [45].
The presence of C. auris in a non-hospital settings has been previously described in a study on
potentially pathogenic fungi in swimming pools in the Netherlands and found out three C. auris
isolates in the water of two different swimming pools, which indicates a wider presence of C. auris,
not restricted to hospital environment [46]. However, much more data are needed to understand the
ecological niche of this species and ccommunity-based studies are necessary to understand the risk of
transmission outside healthcare settings.
2.5. What Are the Recommended Infections Control Practices in Healthcare Facilities for the Prevention of
C. auris Spreading?
For all forms of candidiasis, including the mucocutaneous ones, CDC recommended standard
precautions of infection control for preventing transmission in health care setting.
However, like in other microorganisms, the infection control practices are not specific to one
genus or species but dependent on other factors like contagiousness/spreading ability, pathogenicity
or virulence (high morbidity and mortality in the general population or in patients with particular
susceptibilities), difficult treatment (multi- or pan-resistence, innate or acquired) or because they are
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emerging microorganisms [47,48]. C. auris is an emerging microorganism, with proven high ability to
spread and multidrug resistance that makes it an epidemiologically important microorganism that
in addition to basic infection control measures requires the implementation of contact precautions of
infection control [49,50].
Detection of even a single case of C. auris should trigger an epidemiological investigation of an
outbreak [51]. This requires, as has already been stated, that microbiology laboratories could identify
precisely C. auris and further implementation of lab-based warning systems. In the presence of a
positive case, it is necessary to determine the magnitude and severity of the problem, advise key
practitioners, notify the competent authorities and management board of the institution, set up an
outbreak management team, and develop a strategy plan for dissemination control with respective
monitoring. Several recommendations, listed in Table 1, have been published by the Centers for
Disease Control and Prevention [51], the European Center for Disease Control [52], Public Health
England [53] and National Institute for communicable diseases [54].
Usually, outbreaks follow an exponential increase in the number of affected patients. Patients
potentially or already colonized should be placed in single rooms with contact isolation precautions.
Hand hygiene (with alcohol or chlorhexidine hand rubs), wearing of protective clothing, and skin and
environmental/equipment decontamination should be performed to prevent ongoing transmission.
It is advisable to implement stringent infection control measures for all positive C. auris patients,
including strict isolation in a single-patient room or cohorting for the duration of their hospital stay.
Screening should be applied for contacts and patients previously hospitalized in healthcare settings
where C. auris isolation was confirmed. It is mandatory to trace contacts with the aim to achieve early
identification and screening of possible colonized patients that might be responsible for persistence
of C. auris [55]. It is necessary also to form cohorts with their direct patient contacts and to perform
extensive screening of them (look for the yeast presence in clinical and screening samples as nose,
axilla, groin, throat, rectum or faeces, vascular line exit sites, urine, wounds, drains and respiratory
specimens), as well as ceasing new admissions in the affected areas. If the outbreak persists despite all
measures implemented, then it will be necessary to include professionals in the screening [51,56].
Healthcare personnel caring for patients with C. auris must faultlessly adhere to the five moments of
hand hygiene (before touching a patient, before clean/aseptic procedures, after body fluid exposure/risk,
after touching a patient, and after touching patient surroundings). This is the single most important
practice to reduce the transmission of infectious agents in healthcare settings, and use adequate
Personal Protective Equipment (wear a gown and gloves) in all interactions that may involve contact
with the patient or the patient’s environment [39,57]. For now, CDC or ECDC do not advocate a
decolonization protocol or change the antiseptic alcohol-based solution used in hand hygiene. Skin and
environmental/equipment decontamination should be performed to prevent ongoing transmission [55].
Survival in the ICU environment appeared to facilitate the persistence and transmission of this organism
and lead to the vicious cycle of colonization-spread-infection, very difficult to control. Reusable patient
equipment may serve as a source of health care-associated outbreaks of infection with C. auris [7].
Thus, it is very important to have a cleaning protocol and strengthen the regular decontamination
of the equipment and environment, especially high-touch areas with a chlorine-based product. For
terminal cleaning/disinfection a ‘no-touch’ automated room disinfection system must be considered
(as hydrogen peroxide or UV-C) to eliminate C. auris transmission [56,58].
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Table 1. Recommendations from the different institutions regarding infection control practices in C. auris.
Institutions Recommendations for C. auris Infection Control Practices
Public Health England Isolation of all patients colonised or infected with the organism in a single room, ideally with ensuite facilities, whereverpossible, side rooms or cohorted
Centre for Opportunistic, Tropical and
Hospital
Minimization of the number of staff who care for the C. auris patient. If multiple C. auris patients are present in a facility,
consider cohorting staff that care for these patients.
European Center for Disease Control Equipment used for the infected/colonised patient should not be shared with other patients on the ward unlessbetween-patient decontamination can be assured.
Center for Disease Control and Prevention Strict adherence of healthcare workers to standard precautions including hand hygiene using soap and water followed byalcohol hand rub on dry hands
Personal protective equipment in the form of gloves and aprons
Affected patients, visitors and family members should be briefed about the importance of hand hygiene and visitors
encouraged to use protective aprons
Single-patient use items such as blood pressure cuffs and pillows should be considered
If a patient needs to be taken out of the side room or bay to theatre, procedure room, or for imaging, they should be
scheduled last on the list for the day and the environment cleaned
Hypochlorite is currently recommended for cleaning of the environment at 1000 ppm of available chlorine
CDC recommends use of an Environmental Protection Agency (EPA)-registered hospital-grade disinfectant effective
against Clostridioides difficile spores
If any noncontact disinfection is used (e.g., gaseous hydrogen peroxide or UV), full cleaning and disinfection preceding it
should still occur
Routine screening for C. auris at the time of hospital admission is not currently recommended
Periodic reassessments for presence of C. auris colonization (e.g., every 3 months) for a patient with known C. auris
colonization could help inform duration of infection control measures
“Flag” the patient’s record to institute recommended infection control measures in case of re-admission
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2.6. Why Is C. auris Considered an Emerging Multidrug-Resistant (MDR) Yeast? Are There Other Attributes
in C. auris Different from Other Candida Species?
While distantly related to C. albicans and C. glabrata, C. auris is closely related to rarely observed
and often multidrug-resistant species from the C. haemulonii clade. C. auris and their phylogenetically
related species C. haemulonii, C. duobushaemulonii, and C. pseudohaemulonii represent an emerging clade
of invasive fungal pathogens, all displaying a multidrug-resistant (MDR) profile, most commonly to
amphotericin B and also reduced susceptibility to azoles and echinocandins [59]. A high proportion
of C. auris isolates are resistant to more than one class of antifungal agents (azoles, echinocandins
and polyens). This indicates that probably more than one molecular mechanisms are underlying this
resistance and this is currently under investigation. Efflux pump activity contributes to azole resistance
in other Candida species and recent studies suggest their importance in C. auris as well [60–62].
Most of the genes associated with drug resistance and pathogenesis in C. albicans are conserved in
C. auris, C. haemulonii, C. duobushaemulonii, and C. pseudohaemulonii. Orthologs genes noted to confer
drug resistance in C. albicans were identified in C. auris; this resistance occurs either by acquiring point
mutations, increasing transcription, or copy number variation [41,60].
Recently, it was shown that older C. auris cells presented enhanced fluconazole associated
with increased rhodamine 6G (R6G) efflux [63]. The higher efflux in the older cells correlated with
overexpression of the efflux pump encoding gene CDR1 (fourfold). On the other hand, Hsp90 enables
tolerance of clinical isolates to azoles [64]. However, high-level azole resistance was independent
of Hsp90, but dependent on the ABC transporter CDR1, deletion of which resulted in abrogated
resistance. Inhibition of Hsp90 blocks calcineurin-dependent stress responses and cell wall integrity
signalling, thereby reducing antifungal tolerance of clinical isolates and transforming azole activity
from fungistatic to fungicidal [64].
The annotated genome assemblies of C. auris, C. haemulonii, C. duobushaemulonii, and
C. pseudohaemulonii contain a single copy of the ERG11 azole target and the UPC2 transcription
factor that regulates the expression of genes in the ergosterol pathway, as well as all the gene
components of the ergosterol biosynthesis pathway [41].
An eightfold upregulation of the azole target encoding gene ERG11 was noted in C. auris older
cells. Analysis of genomic DNA from older cells by qPCR indicates that transient gene duplication of
CDR1 and ERG11 causes the observed age-dependent enhanced fluconazole tolerance [63]. Twelve
ERG11 mutations, which have been found in fluconazole-resistant, but not wild-type C. albicans, have
been found in C. auris in silico analysis. Three of these mutations have been directly linked to drug
resistance in C. albicans, suggesting that they contribute to the resistance observed in C. auris as well [10].
Furthermore, detection of azole resistant mutations by comparing Erg11 amino acid sequences
between C. albicans and C. auris showed that alterations at azole-resistance codons in C. albicans were
present in C. auris isolates. These substitutions were strongly associated with country-wise-specific
geographic clades [11]. Resistance is probably inducible under antifungal pressure, resulting in rapid
mutational changes [64].
Elevated echinocandin minimal effective concentrations (MECs) are likely the result of FKS
mutations observed in C. auris isolates, such as the S639F mutation observed in isolates from India [65].
These mutations correspond to known mutations in other Candida species, which have been directly
linked to echinocandin resistance [66].
Resistance to amphotericin B in C. auris is not well understood yet but whole-genome sequencing of
resistant isolates identified four novel nonsynonymous mutations, highlighting a potential association
with resistance. These mutations included those in genes with homology a transcription factors of
C. albicans and a membrane transporter [45].
2.7. Which Factors May Contribute to the High Mortality Associated to C. auris Infections?
Patients infected or colonized with C. auris present frequently several underlying health conditions
or comorbidities (diabetes, chronic/acute kidney failure/pathologies, immunosuppression conditions,
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solid tumour/malignancies, cardiovascular diseases, and liver diseases) [43]. These patients have often
undergone multiple medical interventions, including surgical procedures, mechanical ventilation,
vascular catheterization, and gastrostomy tube placement [11,49]. The most important predisposing
factors to Candida infections are iatrogenic. Of these, probably the most significant is the exposure to
broad-spectrum antibiotics for treatment and prophylaxis of several infectious conditions.
The pathogenicity of C. auris was explored in an invertebrate moth larvae (Galleria mellonela) model
of invasive candidiasis, and found that some C. auris strains to be considerably more virulent than
other no filamentous Candida isolates, and to a level comparable to that of C. albicans [67]. Contrarily to
C. albicans, where morphological transition from nonpathogenic yeast form to pathogenic hyphae form
has been identified as initial step of pathogenesis, no morphological transition has been observed in
C. auris isolates.
The morphology of C. auris on the rich media YPD and YPD plus 10% NaCl has a round appearance
on the former medium, but an elongated shape on the latter. Interestingly, a small portion of highly
elongated and pseudohyphae-like forms were observed when grown on YPD plus 10% NaCl [68].
These results suggest that high-salt stress may result in incomplete cell division, leading to the formation
of pseudohyphae-like forms. C. auris fails to form chlamydospores after growth on cornmeal agar
when incubated for 3 days at 30 ◦C and does not germinate when incubated with fetal bovine serum.
C. auris undergoes a morphogenetic transition from yeast to filamentous growth in response to HSP90
depletion or cell cycle arrest but not in response to other cues that induce C. albicans filamentation [64].
Recently, a novel phenotypic switching system in C. auris has been reported which transits cells in
three different cell types—typical yeast, filamentation-competent yeast and filamentous cells [69].
In addition to its role in enabling the emergence and maintenance of azole resistance, Hsp90 governs
temperature-dependent morphogenesis in C. albicans. The ability of C. albicans to transition between
yeast and filamentous forms is a key virulence trait that is triggered by a wide variety of environmental
cues [70]. However, exposure to various cues that induce C. albicans filamentation does not induce
morphogenesis in C. auris, suggesting alternative pathways regarding the yeast-to-filament transition
between the two Candida species [71]. Higher levels of salt and higher temperatures seem to be the
ideal conditions for C. auris development [32].
C. auris has been described as highly virulent also due to its ability to form biofilms [46].
Candida species are adapted to surface adherence and biofilms formation in body surfaces as well
prosthetic devices, including urinary catheters and intravascular devices [72]. Biofilm formation is a
strain-dependent trait in C. auris, strongly associated with the type and phenotypic behaviour of the
isolates. Aggregative and nonaggregative phenotypes were found to be predominantly associated
with colonising and clinical isolates of C. auris, respectively [73]. Furthermore, multiple transporter
genes and protein kinases, which may facilitate the acquisition of drug resistance, have been identified
in C. auris [51]. C. auris biofilms did not show susceptibility to any antifungal agent, showing minimal
biofilm eradication concentration (MBECs) that were up to 512-fold higher than the minimal inhibitory
concentrations (MICs) [74].
How biofilm formation by C. auris may influence immunity is unknown, however biofilms
formed by other Candida species resist phagocytic killing [75,76]. All arms of the immune system
are involved in the response of Candida infections. Lymphocytes are crucial to the development of
cell-mediated immunity, and monocytes and neutrophils damage and destroy pseudohyphae and
blastospores. Deficiencies in T-helper 17 cell line impair the mucosal immune response to C. albicans,
and patients with significant neutrophil dysfunction or leukopenia have a strong propensity toward
the development of candidemia.
The host immune response induces the release of pro-and anti-inflammatory cytokines in order
to mediate the immune response [77]. The innate immune cells may suffer an enhancement on
cytokine release by monocytes and macrophages in a T-cell independent manner. Candida species have
developed evasion mechanisms that may circumvent the host immune response [78,79].
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Neutropenia, a common risk factor for invasive candidiasis has not been reported for C. auris
infection [11,80]. Human neutrophils failed to engage C. auris, phagocytose the yeasts, or release
neutrophil extra-cellular trap (NET) formation [81]. Mice deficient in neutrophil elastase, an essential
NET component, survived to high-dose C. auris intravenous challenge [82].
Little is known regarding the mechanisms underlying this phenomenon or how the genetic
diversity of C. auris may influence evasion of neutrophil engagement. In contrast to C. albicans, similar
pattern of phagocyte evasion has been observed for C. lusitaniae, a species phylogenetically close to
C. auris [83]. This prompts the question of an altered fungal component that is shared for the two
species, but divergent from more distantly related Candida species [84]. Peripheral blood mononuclear
cells appear to elicit unique cytokine responses encounter with C. auris and C. albicans, suggesting
exposure to different fungal components [85]. The observation that neutrophil exhibit reduced activity
against C. auris may contribute to poor outcome for patients with invasive disease even for patients
treated with appropriate antifungals [11,84].
Despite the results obtained regarding the possible effect of NETs, in the same study the authors
also used inbred mouse strains highly susceptible for C. auris invasive infection. This A/J mouse strain
carries a loss-of-function mutation in the structural gene for the C5 component of the complement
pathway, that plays several critical roles in the host response to infection, including target lysis and
phagocyte recruitment [82].
C. auris infections are currently associated with candidemia, high mortalities, persistent fungemia
and therapeutic failure at risk patients, many of whom have multi comorbidities. The mortality rates
have varied significantly among geographic regions, with risk factors ranging from the presence of
invasive devices to immunocompromised conditions [43,86]. Mortality rates from initial studies were
concerning, although C. auris—attributable mortality cannot be established from those studies. As such,
the overall attributable mortality rates are unclear. The number of deaths attributable to candidemia,
as opposed to underlying medical conditions, may be difficult to quantify [62]. The significance of C.
auris as a human pathogen remains unclear.
2.8. Does C. auris Isolated from Sites Other Than the Blood Stream, such as Urine and Respiratory Tract,
Represent Infections or Colonizations?
C. auris seems to have a special predilection for the skin. Data from swabs taken to assess patients
for C. auris colonization show that the axilla and groin are the highest yield sites to detect colonization,
followed by nares [10,21]. Specimens from urine, stool, vagina, and rectum have also yielded C. auris.
Despite the majority of Candida species can cause oral or esophageal disease, C. auris is not frequently
reported at these sites. The activity of a salivary cationic peptide, histatin 5, against C. auris was
examined and the vast majority of isolates were found to be highly sensitive to this peptide, particularly
those exhibiting antifungal resistance, which may explain the low frequency of C. auris isolation in
those sites [87]. Patients with clinical infection with C. auris were typically found to be colonized in
noninvasive sites, like skin, long after resolution of invasive infection. Patients may become colonized
with C. auris without active infection. Although asymptomatic colonization with C. auris does not
require antifungal treatment, it is important to identify individuals who are colonized [10]. Previous
colonization can lead to invasive infections as well as to outbreaks. Patients who were colonized with
C. auris can develop an invasive bloodstream infection days to months after becoming colonized [10].
Candidemia usually occurs after an event, such as the placement of a new line or tube, which provides
the opportunity to introduce the organism from the skin into the bloodstream.
In a study of a C. auris outbreak in an intensive care setting, the risk for colonization or infection
was associated with exposure to axillary temperature monitoring [7]. Whole-genome sequencing
found that the patient and probe isolates were all highly related.
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2.9. How Can the Clinical Presentation of an Infection Caused by C. auris Be Distinguished from That by Other
Candida Species?
The incidence of C. auris infections is significantly higher in patients with primary or acquired
immunosuppression, secondary to therapeutic management of hematologic malignancies, bone marrow
transplantation, and other condition requiring immunosuppressive agents [18,39]. A donor-derive
transmission of C. auris during lung transplantation was also described [88]. Nevertheless, neutropenia
is a common risk factor for invasive candidiasis that has not been reported for C. auris infection [11,80].
The unexpected fitness of C. auris in several immunocompetent animal models suggests that this
species may withstand host immune responses that are typically sufficient to prevent invasive disease
caused by other Candida species [82].
C. auris has been documented to cause infections in patients of all ages. In most cases, clinical
presentation is nonspecific and it is often difficult to differentiate between other types of systemic
infections. Most of the reported cases were isolated from blood and other deep-seated sites of infection
(including invasive devices and catheters tips) [43].
Isolations from nonsterile body sites (lungs, urinary tract, skin and soft tissue, and genital
apparatus) may more likely represent colonization rather than infection. As for other Candida species,
the presence of signs and symptoms of infections of the site where C. auris has been isolated from can
help to differentiate between simple colonization and infection [89].
2.10. How Does First-Line Therapy for C. auris Infections Differ from Therapy for Other Candida Species?
The choosing of initial antifungal therapy to an invasive candidiasis, depends of several important
factors, such as the source of infection, severity of the illness, evidence to suggest involvement of
central nervous system or cardiac valves, presence of including central venous catheter and other
intravascular devices, comorbidities, underlying disorders, especially immunosuppression, and the
susceptibility patterns of Candida species.
More than 95% of invasive disease is caused by the most commons pathogens C. albicans, C. glabrata,
C. tropicalis, C. parapsilosis, and P. kudriavzevii. According to data from the United States, C. albicans
has a low incidence of fluconazole resistance, approximately 0.5%–2%. C. tropicalis, C. parapsilosis,
and C. glabrata, on the other hand, have higher rates at 4%–9%, 2%–6%, and 11%–13%, respectively.
The emerging yeast C. auris can exhibit a rate of resistance to fluconazole as high as 93% [4].
Broadly speaking, the pharmacological treatment of candidemia comprises three antifungal
groups: amphotericin B-based preparations, azoles, and echinocandins. Fluconazole is the drug of
choice as initial treatment in most cases of candidemia, in stable patients without previous intake of
azoles. Lipid formulation amphotericin B is a good choice, in patients with proven intolerance, and
limited availability, to other antifungal agents. The echinocandins demonstrate significant fungicidal
activity against most Candida species [90]. However, these agents are only available as parenteral
preparations. Despite this limitation, the efficacy, few drug interactions, and concerns about fluconazole
resistance have led echinocandin as recommended initial therapy for candidemia in non-neutropenic
or neutropenic patients. The change in the treatment scheme from echinocandin to fluconazole is
recommended after a 5–7 days period, in patients whose Candida species is sensitive to fluconazole,
and are clinically stable [89]
Although susceptible C. auris strains, specifically to fluconazole, have been described, most C. auris
strains have been reported to be high resistant to fluconazole and/or to other azoles, and to amphotericin
B, with a minority being resistant to 5-flucytosine and the echinocandins [43]. Almost half of isolates
are multidrug-resistant (resistant to ≥ 2 antifungal classes), and a low number (4%) exhibit resistance
to all classes of antifungals [11,14,91]. Higher resistance to fluconazole, in a Candida non-albicans
species, has become one of the distinguishing characteristics of a potential C. auris infection [51]. Efflux
pumps, mutations in the ERG and FKS genes, and biofilm formations are potential C. auris resistance
mechanisms [41,92,93].
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C. auris invasive infections represent a therapeutic challenge, and no consensus exists for optima
treatment. Based on the most frequent resistance profiles, micafungin is the recommended first-line
treatment for most C. auris infections in adults; however, this treatment is expensive and is not
easily available in countries with more limited resources. Patients should be monitored closely for
resolution of infection, given micafungin resistance has developed in patients after exposure to the
drug. Switching to, or adding, liposomal amphotericin B or isavuconazole could be considered, when
no clinical response or persistent fungemia for > 5 days is observed [94,95]. For neonates and infants
under 2 months of age, amphotericin B is recommended as the first line treatment, and echinocandin
should only be considered in rare circumstances and only after checking that the central nervous
system has not been affected [96]. Due to echinocandins limited penetration into the central nervous
system, other antifungal agents such as flucytosine, posaconazole, and isavuconazole could be used,
depending the isolate in vitro susceptibility.
Candidemia management includes not only early antifungal therapy but also a wide range of
measures, such as drainage of collections, central venous catheter or other devices removal, and if blood
cultures remain positive, then search for a metastatic focus, such as an abscess or endocarditis [89].
The duration of antifungal treatment in candidemia is generally determined by the individual clinical
and mycological response to therapy. It should be continued at least for two weeks after blood cultures
become negative [89]. The treatment of colonization without evidence of active infection is strongly
discouraged [12].
There is an urgent need to expand the antifungal armamentarium, especially in the face of rising
incidence and continuous spread of multidrug resistant isolates of C. auris. Among some newly
investigated compounds, SCY-078, a novel triterpene glucan synthase inhibitor, has shown promising
in vitro results against C. auris [97].
2.11. Which Are the Most Recent Tools Available for C. auris Detection and Identification?
CDC advises Candida identification to species-level in the following situations: (a) when clinically
indicated in the care of a patient; (b) when a case of C. auris infection or colonization has been detected
in a facility or unit; (c) when a patient has had an overnight stay in a health care facility in the previous
6 months in a country with C. auris transmission. Laboratories should also review past records to
identify confirmed or suspected cases, as well as conduct prospective surveillance [98]. Because contact
precautions and other infection control measures are not recommended for most other Candida species
but are essential for the control of C. auris, species identification is important not only for infection
control but also for treatment [99].
As previously referred, diagnostic laboratories using standard biochemical identification can only
identify C. auris if the system contains a reference in its database. As databases are being updated,
accurate identification becomes more possible. Even so, misidentifications of strains from certain
C. auris clades have been reported and, for example, all VITEK identifications of C. duobushaemulonii
should be forwarded for further identification [100]. In addition, multidrug resistant Candida isolates
should also be precisely identified. Thus, laboratories can reliably identify an isolate by sequencing
the D1–D2 region of the 28s rDNA or the internal transcribed spacer (ITS) regions of rDNA, C. auris
specific PCR/qPCR or matrix assisted laser desorption ionization-time of flight mass spectrometry
(MALDI-TOF MS) performed directly from the culture may be used as confirmatory identification
methods [101–107].
Regarding DNA detection directly from the biologic product, several molecular-based assays have
been recently developed, from conventional PCR through real-time PCR, to more complex T2 magnetic
resonance or Loop-mediated Isothermal Amplification (LAMP) [107–110]. Most of the developed
assays (commercial or in-house) are characterized by their high sensitivity and specificity.
Molecular methods are also being applied to detect resistance in C. auris using allele-specific
molecular beacons and DNA melting curve analysis following asymmetric PCR. A duplex ERG11 assay
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and a simplex FKS1 HS1 assay were developed to identify the most prominent resistance-associated
mutations concerning resistance to azoles and echinocandins, respectively [111].
2.12. What Do We Need to Study to Advance Our Understanding of C. auris?—Future Perspectives
The implementation of antimicrobial stewardship programs is warranted to minimize unnecessary
antibiotic use. Stewardship teams can also assist with rapid case identification, appropriate management,
and coordinate with infection prevention to minimize transmission [12].
There are multiple unanswered questions regarding C. auris, population prevalence, and
environmental contamination, effectiveness of infection prevention and control, and impact on
patient mortality [21,112]. In order to understand how it spreads and discover possible reservoirs, it
is essential to know the ecology, the natural environment, and distribution of this species. It is also
important to explore possible reasons to this recent emergence, namely the environmental presence of
azoles or the potential effect of climate change, as global warming and UV radiation, on this sudden
emergence [15–17]. Community-based studies will help clarify whether C. auris is associated mainly to
hospital infections or whether there is widespread hospital and community carriage [21].
Regarding the microorganism itself, more whole genome sequencing studies are needed to unveil
mechanisms of resistance and virulence attributes and those discoveries must be validated with in vitro
and in vivo models. Furthermore, serial studies on antifungal susceptibility should be done in order to
establish clinical breakpoint to the different antifungals.
Despite what is already known, much more has yet to be explored in C. auris. Scientific and clinical
communities around the world must continue to develop research project towards the discovery of the
ecological niche of this organism, a better understanding of specific genes associated to virulence that
could be used as antifungal targets and the study of host genetic markers that can be associated with a
worse outcome.
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